Abstract
NSAIDs are frequently used in clinical practice and they account for approximately 5–10% of all drug prescriptions. NSAID use has been associated with a risk of adverse events, which have a relevant impact on morbidity and mortality and account for a substantial increment of healthcare costs. Less common, but clinically relevant, adverse events associated with NSAID use are the impairment of the CNS and, particularly, the appearance of psychiatric symptoms. These symptoms include changes in cognition, mood state and even precipitation or exacerbation of pre-existing psychiatric disorders. This article aims to review the medical literature on published reports of NSAID-related psychiatric adverse events, identify risk factors for these events and describe mechanisms potentially involved in their onset.
We identified 27 reports with data on 453 cases of NSAID-related psychiatric adverse events. Data suggest that individuals who may be particularly susceptible to such events include patients with a history of psychiatric illness and possibly parturients. Indometacin and selective cyclo-oxygenase (COX)-2 inhibitors were the most frequently reported culprit drugs; however, whether this reflects an increased incidence with these drugs compared with other NSAIDs or factors such as usage or reporting patterns is unknown.
A possible explanation for the psychiatric effect of NSAIDs resides in the modulation of central neurotransmission by prostaglandins, the synthesis of which is inhibited by NSAIDs. COX-2 is a key enzyme in this process since its activity is localised in distal dendrites and dendritic spines, which are cellular specialisations involved in synaptic signalling. Dopamine is considered the most relevant neurotransmitter involved in this phenomenon.
Psychiatric symptoms are a rare but relevant complication of NSAID use. This effect is probably a consequence of impairment in neurotransmission modulated by prostaglandins when NSAIDs are used by susceptible individuals. These drugs should be used with caution in high-risk individuals with pre-existing psychiatric illness, and caution may also be advisable in the postpartum period. To date, reports of NSAID-related psychiatric adverse events have most commonly involved indometacin and selective COX-2 inhibitors. Prescribers should consider warning patients of the possibility of an acute neuropsychiatric event when traditional NSAIDs or selective COX-2 inhibitors are prescribed.
Similar content being viewed by others
References
Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med 2001 Jan 8; 110(1A): 4S–7S
Paulose-Ram R, Hirsch R, Dillon C, et al. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 2003 Jun; 12(4): 315–26
Lipsky PE. The role of COX-2-specific inhibitors in clinical practice. Am J Med 2001 Feb 19; 110 Suppl. 3A: 1S–2S
Vane JR, Botting RM. Mechanism of action of antiinflammatory drugs. Int J Tissue React 1998; 20(1): 3–15
Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995 Mar 30; 332(13): 848–54
Langman MJ, Cheng KK, Gilman EA, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000 Jun 17; 320(7250): 1642–6
Onder G, Penninx BW, Landi F, et al. Depression and adverse drug reactions among hospitalized older adults. Arch Intern Med 2003 Feb 10; 163(3): 301–5
Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002 Dec; 50(12): 1962–8
Rodriguez-Monguio R, Otero M, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003; 21(9): 623–50
Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (Pt I). Drugs Aging 1991 Mar; 1(2): 130–43
Pilotto A, Franceschi M, Leandro G, et al. NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging 2003; 20(9): 701–10
Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000 Mar 1; 151(5): 488–96
Bleumink GS, Feenstra J, Sturkenboom MC, et al. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003; 63(6): 525–34
Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 Aug 22–29; 286(8): 954–9
Jiang HK, Chang DM. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clin Rheumatol 1999; 18(4): 339–45
Clark DW, Ghose K. Neuropsychiatric reactions to nonsteroidal anti-inflammatory drugs (NSAIDs): the New Zealand experience. Drug Saf 1992 Nov–Dec; 7(6): 460–5
Clunie M, Crone LA, Klassen L, et al. Psychiatric side effects of indomethacin in parturients. Can J Anaesth 2003 Jun–Jul; 50(6): 586–8
Celecoxib (Celebrex™): 1 year later. Canadian ADR Newsletter 2000 Apr; 10(2): 1–3
Coulter D. Acute psychiatric reactions with cox-2 inhibitors. Prescriber Update 2002 Jul; 23(2): 21
Acute neuropsychiatric events with celecoxib and rofecoxib. Aust Adv Drug Reactions Bull 2003; 22(1): 3
Boyle AC. Indomethacin and peptic ulcer [letter]. BMJ 1965 May 1; 5443: 1191
Rothermich NO. An extended study of indomethacin. I: clinical pharmacology. JAMA 1966 Feb 14; 195(7): 531–6
Thompson M, Percy JS. Further experience with indomethacin in the treatment of rheumatic disorders. BMJ 1966 Jan 8; 5479: 80–3
Carney MW. Paranoid psychosis with indomethacin. BMJ 1977 Oct 15; 2(6093): 994–5
Gotz V. Paranoid psychosis with indomethacin [letter]. BMJ 1978 Jan 7; 1(6104): 49
Kruis R, Barger R. Paranoid psychosis with sulindac [letter]. JAMA 1980 Apr 11; 243(14): 1420
Thornton TL. Delirium associated with sulindac [letter]. JAMA 1980 Apr 25; 243(16): 1630–1
Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982 Aug; 25(8): 1013–5
Griffith JD, Smith CH, Smith RC. Paranoid psychosis in a patient receiving ibuprofen, a prostaglandin synthesis inhibitor: case report. J Clin Psychiatry 1982 Dec; 43(12): 499–500
Schwartz JI, Moura RJ. Severe depersonalization and anxiety associated with indomethacin. South Med J 1983 May; 76(5): 679–80
Sotsky SM, Tossell JW. Tolmetin induction of mania. Psychosomatics 1984 Aug; 25(8): 626–8
Browning CH. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int J Psychiatry Med 1996; 26(1): 25–34
Mallet L, Kuyumjian J. Indomethacin-induced behavioral changes in an elderly patient with dementia. Ann Pharmacother 1998 Feb; 32(2): 201–3
Ritter A, Eskin B. Ibuprofen overdose presenting with severe agitation and hypothermia. Am J Emerg Med 1998 Sep; 16(5): 549–50
Nassif JM, Ritter MA. Indomethacin-induced postoperative psychosis. J Arthroplasty 1999 Sep; 14(6): 769–70
Tharumaratnam D, Bashford S, Khan SA. Indomethacin induced psychosis. Postgrad Med J 2000 Nov; 76(901): 736–7
Lantz MS, Giambanco V. Acute onset of auditory hallucinations after initiation of celecoxib therapy. Am J Psychiatry 2000 Jun; 157(6): 1022–3
Macknight C, Rojas-Fernandez CH. Celecoxib- and rofecoxibinduced delirium. J Neuropsychiatry Clin Neurosci 2001 Spring; 13(2): 305–6
Katz N, Zemishlany Z, Weizman A. Ibuprofen and psychotic exacerbation. Am J Psychiatry 2002 Sep 1; 159(9): 1606–7
Bernstein AL, Werlin A. Pseudodementia associated with use of ibuprofen. Ann Pharmacother 2003 Jan; 37(1): 80–2
Eser D, Zwanzger P, Rupprecht R. Carbamazepine treatment of adverse psychiatric effects after treatment with the nonsteroidal anti-inflammatory drug piroxicam. J Clin Psychiatry 2003 Jul; 64(7): 852–4
Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97–120
Kaufmann WE, Andreasson KI, Isakson PC, et al. Cyclooxygenases and the central nervous system. Prostaglandins 1997 Sep; 54(3): 601–24
Horrobin DF. The roles of prostaglandins and prolactin in depression, mania and schizophrenia. Postgrad Med J 1977; 53 Suppl. 4: 160–5
Horrobin DF, Manku MS. Possible role of prostaglandin E1 in the affective disorders and in alcoholism. BMJ 1980 Jun 7; 280(6228): 1363–6
Laruelle M, Abi-Dargham A, Gil R, et al. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999 Jul 1; 46(1): 56–72
Ellison G. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res Brain Res Rev 1994 May; 19(2): 223–39
Ross BM, Brooks RJ, Lee M, et al. Cyclooxygenase inhibitor modulation of dopamine-related behaviours. Eur J Pharmacol 2002 Aug 23; 450(2): 141–51
van Kammen DP, Yao JK, Goetz K. Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann N Y Acad Sci 1989; 559: 411–23
Kaiya H, Imai H, Muramatsu Y, et al. Platelet aggregation response in schizophrenia and prostaglandin El. Psychiatry Res 1983 Aug; 9(4): 309–18
Vaddadi K. Dyskinesias and their treatment with essential fatty acids: a review. Prostaglandins Leukot Essent Fatty Acids 1996 Aug; 55(1–2): 89–94
Kanof PD, Davidson M, Johns CA, et al. Clinical correlates of platelet prostaglandin receptor subsensitivity in schizophrenia. Am J Psychiatry 1987 Dec; 144(12): 1556–60
Vinogradov S, Csernansky JG. Postpartum psychosis with abnormal movements: dopamine supersensitivity unmasked by withdrawal of endogenous estrogens? J Clin Psychiatry 1990 Sep; 51(9): 365–6
Fink G, Sumner BE, Rosie R, et al. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 1996 Jun; 16(3): 325–44
Haag M. Essential fatty acids and the brain. Can J Psychiatry 2003 Apr; 48(3): 195–203
Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs: aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991 Jul; 151(7): 1309–13
Scideman P, von Arbin M. Cerebral blood flow and indomethacin drug levels in subjects with and without central nervous side effects. Br J Clin Pharmacol 1991 Apr; 31(4): 429–32
Onder G, Gambassi G, Scales CJ, et al. Adverse drug reactions and cognitive function among hospitalized older adults. Eur J Clin Pharmacol 2002 Aug; 58(5): 371–7
Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997 Jul 28; 157(14): 1531–6
Onder G, Landi F, Cesari M, et al. Inappropriate medication use among hospitalized older adults in Italy: results from the Italian Group of Pharmacoepidemiology in the Elderly. Eur J Clin Pharmacol 2003 Jun; 59(2): 157–62
Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999 Jun 22; 96(13): 7563–8
Muller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002 Jun; 159(6): 1029–34
Acknowledgements
The authors have no conflicts of interest that are directly relevant to the content of this review. The work of Dr Onder was sponsored by the Italian Ministry of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onder, G., Pellicciotti, F., Gambassi, G. et al. NSAID-Related Psychiatric Adverse Events. Drugs 64, 2619–2627 (2004). https://doi.org/10.2165/00003495-200464230-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200464230-00001